2 completed, 2 recruiting, 1 active not recruiting. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
Follow Arvinas Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. ARV-393, Glofitamab - Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase 1 | Recruiting | Arvinas Inc. | 329 | 2024-09-05 | 2026-09-04 |
| A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery ARV-471, Anastrozole, Surgical resection of breast tumor - Breast Cancer | Phase 2 | Completed | Arvinas Inc. | 152 | 2023-02-15 | 2025-08-29 |
| Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer ARV-110 - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Completed | Arvinas Inc. | 248 | 2019-03-01 | 2025-04-01 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1)
Anastrozole (1) · glofitamab (1) · pembrolizumab (1)
United States (5) · Spain (2) · Australia (1) · Canada (1) · Denmark (1) · Georgia (1) · Germany (1)
2023 (1), 2025 (1)